PCSK9 influences heart disease progression through multiple pathways, such as LDL receptor downregulation, which increases LDL levels, inflammation through engagement with Toll-like receptors (TLRs), and clot formation by interacting with platelet glycoprotein IV (CD36) to activate platelets. This evidence concerns the gene CD36 and heart disorder.